Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group

Leukemia, Published online: 21 October 2019; doi:10.1038/s41375-019-0609-3Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group
Source: Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

Authors: Ivan I, Climent F, Mercadal S PMID: 31722786 [PubMed - as supplied by publisher]
Source: Medicina Clinica - Category: General Medicine Tags: Med Clin (Barc) Source Type: research
This article aims to discuss the concept of stigma and its repercussions on persons living with HTLV. The discussion is based on a literature review on the theme and the authors' experience with care for persons affected by the infection and illness. The study found that both HTLV carrier status and HTLV-related illness can be stigmatizing for individuals, who feel inferior for being infected with a potentially serious and even fatal disease, although incompletely understood and loaded with derogatory stereotypes. This situation can have negative repercussions on access to health services, treatment adherence, and pursuit ...
Source: Cadernos de Saude Publica - Category: International Medicine & Public Health Authors: Tags: Cad Saude Publica Source Type: research
ConclusionsPCPs report several barriers in providing care to hematologic malignancy/HCT survivors. Clinical experience with this patient population is associated with greater confidence in providing survivorship care. Several barriers identified by PCPs in providing survivorship care to hematologic malignancy/HCT survivors are potentially addressable by education, clinical decision support tools and guidelines, enhancing clinical experience, and care coordination with hematologist-oncologists.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We examined publication bias and excess significance bias. 63 articles corresponding to 247 meta-analyses were eligible. Nine meta-analyses were classified to have convincing evidence, and 75 were classified as suggestive evidence. The clinical benefit of immunotherapy was supported by convincing evidence in the following settings: anti-PD-1/PD-L1 monoclonal antibody (mAb) therapy for treating advanced melanoma and non-small cell lung cancer (NSCLC), the combination of rituximab and chemotherapy for treating chronic lymphocytic leukemia and B-cell non-Hodgkin’s lymphoma, adoptive cell immunotherapy for NSCLC, and...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Within the last decade, as interest has renewed in finding innovative ways to harness the immune system to treat cancer, chimeric antigen receptor (CAR) T cell therapy has risen to the helm in treatment of relapsed/refractory non-Hodgkin lymphoma (NHL). Engineering a patient's own T cells to directly target CD19-expressing lymphoma/leukemia cells has resulted in unprecedented response rates in heavily pre-treated patients, and the responses have proven durable for most NHL patients who achieve an early complete remission [1 –5].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Conditions:   Leukemia;   Lymphoma Intervention:   Biological: :Anti-CD22-CAR Sponsors:   Kecellitics Biotech Company Ltd;   Hebei Yanda Ludaopei Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Malignant mesothelioma has become the latest deadly cancer linked directly to the rescue, recovery and cleanup efforts following the 9/11 terrorist attack on New York City in 2001. The long-running threat has come to fruition. Eighteen years after Manhattan was engulfed in the asbestos-laced, toxic cloud of dust — caused primarily by the World Trade Center destruction — the first death from pleural mesothelioma attributed to 9/11 has been recorded. Nick Ursta, 52, from the southwestern part of Pennsylvania, died after a year-long battle with the rare cancer. Ursta, a construction worker and fireman by trade, w...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Authors: Morris AL, Colbourne T, Kirkpatrick I, Banerji V Abstract Nontraumatic chylous pleural effusions (chylothorax) and pericardial effusions (chylopericardium) are rare. They can, however, accompany intrathoracic malignancies and, most commonly, lymphomas. An association of chronic lymphocytic leukemia (cll) with chylopericardium has rarely been reported. A 68-year-old woman with cll, previously treated with single-agent fludarabine in the community, developed pleuritic chest pain and a new pericardial effusion. Computed tomography (ct) imaging of her chest revealed a large pericardial effusion with progressiv...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Conclusions: More than half the study patients received ibrutinib therapy at a submaximal dose without evidence of increased frequency of toxicities or disease progression. The rate of ibrutinib discontinuation was lower in our cohort than has been reported in other settings. Submaximal ibrutinib dosing will have to be further systematically evaluated. PMID: 31708654 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Conditions:   Leukemia;   Lymphoma Intervention:   Biological: :Anti-CD22-CAR Sponsors:   Kecellitics Biotech Company Ltd;   Hebei Yanda Ludaopei Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Germany Health | Hematology | Leukemia | Lymphoma | Rituxan | Study